Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Gains from Investment Securities: 2024-2025

Historic Gains from Investment Securities for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $619,000.

  • Zenas BioPharma's Gains from Investment Securities fell 90.27% to $619,000 in Q3 2025 from the same period last year, while for Mar 2025 it was $115,153, marking a year-over-year change of. This contributed to the annual value of $1.1 million for FY2024, which is 1000.00% up from last year.
  • As of Q3 2025, Zenas BioPharma's Gains from Investment Securities stood at $619,000, which was down 7.20% from $667,000 recorded in Q2 2025.
  • Zenas BioPharma's Gains from Investment Securities' 5-year high stood at $6.4 million during Q3 2024, with a 5-year trough of $115,153 in Q1 2025.
  • Over the past 2 years, Zenas BioPharma's median Gains from Investment Securities value was $667,000 (recorded in 2025), while the average stood at $1.8 million.
  • Data for Zenas BioPharma's Gains from Investment Securities shows a maximum YoY tumbled of 90.27% (in 2025) over the last 5 years.
  • Zenas BioPharma's Gains from Investment Securities (Quarterly) stood at $1.0 million in 2024, then plummeted by 90.27% to $619,000 in 2025.
  • Its Gains from Investment Securities was $619,000 in Q3 2025, compared to $667,000 in Q2 2025 and $115,153 in Q1 2025.